Pharma: Page 21
-
Courtesy of Eisai
Eisai and Bristol Myers cancel cancer ADC deal
The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.
By Jonathan Gardner • July 1, 2024 -
Getty Images
Sponsored by Nelson LabsThe right viral safety program can guard against costly bioburden incidents in biopharma development
Viral contamination threatens biopharmaceutical development, making viral clearance and safety essential for risk mitigation.
July 1, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Courtesy of Merck & Co.
Merck’s pneumococcal vaccine gets CDC panel backing
Advisers to the agency unanimously recommended use of Capvaxive in older adults and in certain younger ones, putting it in the same tier as Pfizer's competing Prevnar shot.
By Delilah Alvarado • June 28, 2024 -
Getty Images
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan.
By BioPharma Dive staff • June 28, 2024 -
Kevin C. Cox via Getty Images
RSV vaccine makers’ shares fall as CDC adjusts shot guidance
The new guidance more strongly urges vaccination in adults who are older or at higher risk, but removes a prior recommendation for adults aged 60 to 74 years without certain risk factors.
By Delilah Alvarado • June 27, 2024 -
Getty Images
Novo nixes trial of blood pressure drug it bought in $1.3B deal
The failure of a Phase 3 study led the Wegovy maker to take an accounting charge that will hit its operating profit growth this year.
By Jonathan Gardner • June 26, 2024 -
Getty Images
Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s
Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged.
By BioPharma Dive staff • June 26, 2024 -
Getty Images
Novo to spend $4B on US plant, adding to obesity drug production push
The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.
By Jonathan Gardner • June 25, 2024 -
Getty Images
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data
The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.
By BioPharma Dive staff • June 24, 2024 -
Getty Images
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
By BioPharma Dive staff • June 21, 2024 -
Courtesy of Amazon
Amazon expands drug subscription program to Medicare members
RxPass, which fills prescriptions for generic drugs, is now available to more than 50 million Medicare members after Amazon brought it into compliance with the insurance program’s regulatory standards.
By Rebecca Pifer Parduhn • June 20, 2024 -
Kena Betancur via Getty Images
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
The new vaccine, which Merck will sell as Capvaxive, will compete with Pfizer’s blockbuster Prevnar franchise.
By Delilah Alvarado • June 18, 2024 -
Getty Images
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
By BioPharma Dive staff • June 18, 2024 -
Permission granted by Kevin Trimmer/Ascidian Therapeutics
Roche partners with RNA editing biotech Ascidian
While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.
By Gwendolyn Wu • June 18, 2024 -
Getty Images
Takeda drug for rare types of epilepsy misses goal in late-stage trial
Called soticlestat, the drug had seemed promising in earlier studies for people with Dravet and Lennox-Gastaut syndrome, enough to persuade Takeda to take on full rights to the drug.
By Jonathan Gardner • June 17, 2024 -
Getty Images
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.
By BioPharma Dive staff • June 14, 2024 -
Anna Moneymaker via Getty Images
Supreme Court preserves access to abortion pill in unanimous ruling
The high court said the plaintiffs’ “desire to make a drug less available to others” did not give them standing to challenge the FDA's expansion of mifepristone’s approval.
By Delilah Alvarado • June 13, 2024 -
Getty Images
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.
By BioPharma Dive staff • June 12, 2024 -
Getty Images
New Alzheimer's drugsDonanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
After an FDA panel backed Lilly’s drug three weeks ago, Wall Street analysts noted how its clearance — now granted — could benefit Eisai and Biogen’s rival Leqembi.
By Jonathan Gardner • June 11, 2024 -
Getty Images
ADCs are in focus. Here’s where AstraZeneca, AbbVie hope to take the field next.
Newer components and drug combinations could expand use of the targeted cancer medicines, according to company executives.
By Michael Gibney • June 11, 2024 -
Scott Olson via Getty Images
New Alzheimer's drugsLilly Alzheimer’s drug gets unanimous backing of FDA panel
The expert committee's twin 11-0 votes tees up donanemab for U.S. approval later this year and a market showdown with Leqembi.
By Jacob Bell , Jonathan Gardner • Updated June 11, 2024 -
iStock / South_agency
Sponsored by VeradigmHealth economics and outcomes research: Biopharma and the shift to value-based care
Of the changes sparked by value-based care, perhaps the most valuable for the biopharmaceutical industry to embrace is the use of health economics and outcomes research (HEOR) to better understand a product’s value.
By Amanda Cohen, MPH • June 10, 2024 -
Getty Images
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
By BioPharma Dive staff • June 7, 2024 -
Getty Images
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
An advisory panel is meeting today to discuss whether donanemab is effective across different groups of Alzheimer's patients, and to give input on an unusual dosing strategy used by Lilly.
By Jonathan Gardner • June 6, 2024 -
Courtesy of Seres Therapeutics
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
Seres did not disclose financial details for the deal, but said it would help extend the company's cash runway by one year.
By Kristin Jensen • June 6, 2024
Previous
